Catalytic Degraders Effectively Address Kinase Site Mutations in EML4-ALK Oncogenic Fusions-Reference-Cited by-同舟云学术

Catalytic Degraders Effectively Address Kinase Site Mutations in EML4-ALK Oncogenic Fusions

Published:2023-04-10 Issue:8 Volume:66 Page:5524-5535
ISSN:0022-2623
Container-title:Journal of Medicinal Chemistry
language:en
Short-container-title:J. Med. Chem.

Author:

Gao Yang¹²,Jiang Baishan¹²^ORCID,Kim Hellen¹,Berberich Matthew J.¹^ORCID,Che Jianwei¹²,Donovan Katherine A.²³^ORCID,Hatcher John M.²³,Huerta Fidel¹,Kwiatkowski Nicholas P.¹²³,Liu Yingpeng¹²^ORCID,Liuni Peter P.¹,Metivier Rebecca J.¹^ORCID,Murali Vineeth K.¹,Nowak Radosław P.¹²^ORCID,Zhang Tinghu⁴,Fischer Eric S.¹²³^ORCID,Gray Nathanael S.⁴^ORCID,Jones Lyn H.¹²^ORCID

Affiliation:

1. Center for Protein Degradation, Dana-Farber Cancer Institute, Boston, Massachusetts 02215, United States

2. Department of Biological Chemistry and Molecular Pharmacology, Harvard Medical School, Boston, Massachusetts 02215, United States

3. Department of Cancer Biology, Dana-Farber Cancer Institute, Boston, Massachusetts 02215, United States

4. Department of Chemical and Systems Biology, ChEM-H, Stanford Cancer Institute, School of Medicine, Stanford University, Stanford, California 94305, United States

Funder

National Cancer Institute

Publisher

American Chemical Society (ACS)

Subject

Drug Discovery,Molecular Medicine

Link

https://pubs.acs.org/doi/pdf/10.1021/acs.jmedchem.2c01864

Reference49 articles.

1. Development of targeted protein degradation therapeutics

2. Hijacking the E3 Ubiquitin Ligase Cereblon to Efficiently Target BRD4

3. Phthalimide conjugation as a strategy for in vivo target protein degradation